Multiple sclerosis has attracted regenerative medicine interest because immunosuppression (the standard approach) is imperfect. Stem cells are being studied to repair myelin and modulate immune attack; outcomes are promising but remain early-stage.
Multiple sclerosis, an autoimmune disease where the immune system attacks the myelin sheaths protecting nerve fibres, remains incurable despite decades of immunosuppressive drug development. Standard treatments slow disease progression through immune suppression, but they carry long-term infection risks and don't reverse existing nerve damage. Regenerative medicine researchers have begun exploring stem cell therapy from a different angle: not just suppressing the immune system, but actively promoting remyelination (myelin repair) and perhaps resetting immune tolerance. A few European clinics now offer cell-based treatments for MS, particularly for progressive forms where current drugs are less effective.
What mechanism is proposed? Mesenchymal stem cells produce anti-inflammatory cytokines and growth factors. Oligodendrocyte precursor cells (derived from neural stem cells or induced pluripotent stem cells) can differentiate into myelin-producing oligodendrocytes and potentially repair demyelinated axons. Some protocols combine immune modulation (MSCs reducing attack) with direct myelin repair (neural precursor cells differentiating on damaged nerve fibres). In animal models, both approaches show efficacy. In humans, data is limited but accumulating.
Published evidence in MS is sparse. A few small trials from Europe, the Middle East, and Asia report that intravenous infusion of MSCs or autologous bone-marrow-derived stem cells produces modest improvements in disability scores, MRI measures of inflammation, or disease progression rates. One Bulgarian clinic published a case series of 20 progressive MS patients treated with autologous bone marrow stem cells, reporting stabilisation of disability in 70% over 2–3 years of follow-up. These results are intriguing but not definitive. No large randomised phase 3 trial of stem cell therapy versus placebo in MS has been completed.
Safety concerns exist in MS treatment particularly because MS involves active inflammation. An ill-designed stem cell infusion could theoretically trigger a relapse if the immune system views the cells as foreign. Most protocols now use autologous cells (your own) to reduce this risk. However, MS itself can flare unpredictably. Distinguishing a disease relapse from a treatment-related adverse event requires careful monitoring and expertise. Any clinic offering MS treatment should have neurologists experienced in both MS management and cell therapy, baseline and follow-up MRI protocols, and explicit protocols for managing relapses during treatment.
Current clinical trials are underway in Europe and North America, largely through academic centres rather than commercial clinics. These trials are testing remyelination strategies, immune modulation, and combined approaches. If you have MS and are curious about cell therapy, participating in a formal trial offers more robust safety monitoring and outcome tracking than private clinic treatment. However, if you prefer clinical treatment now, some European clinics offer it—Bulgaria, Spain, and Austria have clinics with MS experience. Assess candidacy carefully, insist on MRI baseline and follow-up protocols, and expect long-term monitoring for at least 2–3 years to assess disease course.
Educational content; outcomes vary by patient and most uses are investigational — consult a physician. Reviewed by the StemCellAtlas editorial team.
GMP-сертифицированная регенеративная медицина в сердце ЕС — от €3 000–8 000, доля от цен США или Германии. Индивидуальные протоколы для пациентов из 50+ стран.
Бесплатная оценка врача